{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:16:24Z","timestamp":1790986584279,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.gtc.2004.12.002","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T19:48:10Z","timestamp":1113508090000},"page":"91-104","source":"Crossref","is-referenced-by-count":64,"title":["Pharmacological Therapies for Obesity"],"prefix":"10.1016","volume":"34","author":[{"given":"Lee M.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gtc.2004.12.002_bib1","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1210\/jc.2004-0341","article-title":"Pharmacological approaches to weight reduction: therapeutic targets","volume":"89","author":"Korner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.gtc.2004.12.002_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00129784-200202040-00004","article-title":"Pharmacotherapy of obesity: currently marketed and upcoming agents","volume":"2","author":"Bays","year":"2002","journal-title":"Am J Cardiovasc Drugs"},{"issue":"12","key":"10.1016\/j.gtc.2004.12.002_bib3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","article-title":"Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Padwal","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"10.1016\/j.gtc.2004.12.002_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","article-title":"Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials","volume":"26","author":"Haddock","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"9","key":"10.1016\/j.gtc.2004.12.002_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1742-1241.2002.tb11352.x","article-title":"The new role of pharmacotherapy for weight reduction in obesity","volume":"56","author":"Fernstrom","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.gtc.2004.12.002_bib6","series-title":"Physicians' desk reference","year":"2005"},{"key":"10.1016\/j.gtc.2004.12.002_bib7","series-title":"Drug Topics Red Book","year":"2004"},{"issue":"4","key":"10.1016\/j.gtc.2004.12.002_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","article-title":"Absence of cardiac valve dysfunction in obese patients treated with sibutramine","volume":"7","author":"Bach","year":"1999","journal-title":"Obes Res"},{"issue":"2","key":"10.1016\/j.gtc.2004.12.002_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"issue":"9248","key":"10.1016\/j.gtc.2004.12.002_bib10","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.gtc.2004.12.002_bib11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Arch Intern Med"},{"issue":"448","key":"10.1016\/j.gtc.2004.12.002_bib12","first-page":"871","article-title":"Antidepressants and the serotonin syndrome in general practice","volume":"49","author":"Mackay","year":"1999","journal-title":"Br J Gen Pract"},{"issue":"4","key":"10.1016\/j.gtc.2004.12.002_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-199958040-00015","article-title":"Orlistat: a review of its use in the management of obesity","volume":"58","author":"Hvizdos","year":"1999","journal-title":"Drugs"},{"issue":"9123","key":"10.1016\/j.gtc.2004.12.002_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gtc.2004.12.002_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gtc.2004.12.002_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0149-2918(03)90009-9","article-title":"Weight management and current options in pharmacotherapy: orlistat and sibutramine","volume":"25","author":"Leung","year":"2003","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.gtc.2004.12.002_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1467-789X.2004.00125.x","article-title":"A systematic review of the clinical effectiveness of orlistat used for the management of obesity","volume":"5","author":"O'Meara","year":"2004","journal-title":"Obes Rev"},{"issue":"8","key":"10.1016\/j.gtc.2004.12.002_bib18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.gtc.2004.12.002_bib19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/oby.2002.142","article-title":"Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms","volume":"10","author":"Jain","year":"2002","journal-title":"Obes Res"},{"issue":"14","key":"10.1016\/j.gtc.2004.12.002_bib20","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1001\/jama.289.14.1820","article-title":"Zonisamide for weight loss in obese adults: a randomized controlled trial","volume":"289","author":"Gadde","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.gtc.2004.12.002_bib21","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/clpt.1992.72","article-title":"Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gtc.2004.12.002_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.1992.69","article-title":"Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo","volume":"51","author":"Weintraub","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.gtc.2004.12.002_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gtc.2004.12.002_bib24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00001573-200209000-00007","article-title":"Appetite suppressants and valvular heart disease","volume":"17","author":"Seghatol","year":"2002","journal-title":"Curr Opin Cardiol"},{"issue":"6","key":"10.1016\/j.gtc.2004.12.002_bib25","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1067\/mhj.2002.126733","article-title":"Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies","volume":"144","author":"Sachdev","year":"2002","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.gtc.2004.12.002_bib26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3949\/ccjm.68.3.208","article-title":"Phenylpropanolamine and stroke: the study, the FDA ruling, the implications","volume":"68","author":"Mersfelder","year":"2001","journal-title":"Cleve Clin J Med"},{"issue":"60","key":"10.1016\/j.gtc.2004.12.002_bib27","first-page":"14853","article-title":"Implementation of the Comprehensive Methamphetamine Control Act of 1996; regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Final rule","volume":"67","year":"2002","journal-title":"Fed Regist"},{"issue":"28","key":"10.1016\/j.gtc.2004.12.002_bib28","first-page":"6787","article-title":"Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule","volume":"69","year":"2004","journal-title":"Fed Regist"},{"issue":"14","key":"10.1016\/j.gtc.2004.12.002_bib29","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","article-title":"Bariatric surgery: a systematic review and meta-analysis","volume":"292","author":"Buchwald","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.gtc.2004.12.002_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00000658-199509000-00011","article-title":"Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus","volume":"222","author":"Pories","year":"1995","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.gtc.2004.12.002_bib31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/oby.2004.151","article-title":"Current and investigational antiobesity agents and obesity therapeutic treatment targets","volume":"12","author":"Bays","year":"2004","journal-title":"Obes Res"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855304001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T23:27:08Z","timestamp":1683070028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855304001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0889855304001293"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2004.12.002","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}